Business
New publication highlights potential of Modi-1
New publication highlights potential of Modi-1.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \n \n RNS Number : 8576Q\n Scancell Holdings Plc\n 24 June 2020\n \n \n \n \n 24 June 2020\n \n \n \n \n \n Scancell Holdings plc\n \n \n (\"Scancell\" or the \"Company\")\n \n \n \n \n \n New publication highlights potential of Modi-1 for hard to treat cancers\n \n \n \n \n \n Modi-1 Phase 1/2 trial expected to start in H1 2021\n \n \n \n \n \n Scancell Holdings plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce the publication of a peer-reviewed research paper in the Journal for ImmunoTherapy of Cancer entitled: \"Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses\".1 The Company also provides an update on current progress and future plans for a Phase 1/2 clinical trial in patients with solid tumours\n including triple negative breast cancer, ovarian cancer, renal cancer and head and neck cancer.\n \n \n \n \n \n Scancell's Moditope® platform represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications (siPTM) such as citrullination. \n The publication describes the first Moditope® vaccine, Modi-1, and its ability to stimulate potent T cell responses that translate into tumour protection in melanoma and ovarian cancer models. The responses were mediated by CD4 T cells and were also able to protect against a second challenge of the tumour confirming the induction of a memory response. The paper also confirms that conjugating the Modi-1 citrullinated peptides to the toll-like receptor-stimulating adjuvant AMPLIVANT®, previously licensed from ISA Pharmaceuticals, allows the therapeutic dose to be reduced by up to 100-fold. The full abstract is detailed below. \n \n \n \n \n \n In January 2020, the Company provided an update on progress towards initiating the Modi-1 Phase 1/2 clinical trial. This has been advanced further with successful completion of GMP drug substance manufacture for all three of the conjugates that comprise the Modi-1 product. Importantly, the technical challenges reported in January concerning one of the peptide components have been successfully resolved, enabling progression to GMP drug product manufacture and formulation of clinical supplies in Q3 2020.\n \n \n &nb...